Gut-Brain-Axis Therapeutics Inc. — SEC Form D Filing

Gut-Brain-Axis Therapeutics Inc. filed an SEC Form D on October 26, 2026, reporting $1.97M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
October 26, 2026
Amount reported
$1.97M
Round stage
Series B+
Industry
Biotechnology
Website
https://gutbrainaxistherapeutics.com/

What the company does

Securities: Equity. Exemption: Rule 506(c). Incorporated: DELAWARE

Problem

Individuals with Autism Spectrum Disorder and Pitt-Hopkins Syndrome frequently suffer from altered gut microbiota, which contributes to gastrointestinal issues and neurological symptoms such as anxiety, irritability, ADHD, and sleep disturbances.

Solution

Gut-Brain-Axis Therapeutics is developing Microbiota Transplant Therapy (MTT), a treatment that restructures the gut microbiome by clearing harmful bacteria and delivering beneficial microbial communities purified from healthy donors.

Why now

Emerging clinical understanding of the gut-brain axis combined with FDA willingness to grant Orphan Drug and Fast Track designations for live biotherapeutic products makes microbiome-targeted neurotherapeutics clinically and commercially viable.

Verdict

This cleared because early clinical signals in refractory pediatric neurodevelopmental cohorts offered just enough biological plausibility to justify an insider bridge, not because investors believed donor-derived microbial transplants represented a scalable biopharma platform. Backers were implicitly betting that orphan designations in high-unmet-need indications like Pitt-Hopkins could bypass standard Chemistry, Manufacturing, and Controls (CMC) scrutiny. However, a sub-$2M round at this stage signals severe capital exhaustion and investor refusal to fund late-stage infrastructure for unstandardized donor graft biology.

Source: SEC EDGAR Form D filing